User:AndrewDunham14/sandbox

From Wikipedia, the free encyclopedia


By effect on function

A mutation becomes an effect on function mutation when the exactitude of functions between a mutated protein and its direct interactor undergoes change. The interactors can be other proteins, molecules, nucleic acids, etc. There are many mutations that fall under the category of by effect on function, but depending on the specificity of the change the mutations listed below will occur. [1]

  • Loss-of-function mutations, also called inactivating mutations, result in the gene product having less or no function (being partially or wholly inactivated). When the allele has a complete loss of function (null allele), it is often called an amorph or amorphic mutation in Muller's morphs schema. Phenotypes associated with such mutations are most often recessive. Exceptions are when the organism is haploid, or when the reduced dosage of a normal gene product is not enough for a normal phenotype (this is called haploinsufficiency). A disease that is caused by a loss-of-function mutation is Gitelman syndrome and cystic fibrosis.[2]
  • Gain-of-function mutations also called activating mutations, change the gene product such that its effect gets stronger (enhanced activation) or even is superseded by a different and abnormal function. When the new allele is created, a heterozygote containing the newly created allele as well as the original will express the new allele; genetically this defines the mutations as dominant phenotypes. Several of Muller's morphs correspond to the gain of function, including hypermorph (increased gene expression) and neomorph (novel function). In December 2017, the U.S. government lifted a temporary ban implemented in 2014 that banned federal funding for any new "gain-of-function" experiments that enhance pathogens "such as Avian influenza, SARS, and the Middle East Respiratory Syndrome or MERS viruses. Many diseases are caused by this mutation including systemic mastocytosis and STAT3 disease.[3]
  • Dominant negative mutations (also called anti-morphic mutations) have an altered gene product that acts antagonistically to the wild-type allele. These mutations usually result in an altered molecular function (often inactive) and are characterized by a dominant or semi-dominant phenotype. In humans, dominant negative mutations have been implicated in cancer (e.g., mutations in genes p53, ATM, CEBPA, and PPARgamma]). Marfan syndrome is caused by mutations in the FBN1 gene, located on chromosome 15, which encodes fibrillin-1, a glycoprotein component of the extracellular matrix. Marfan syndrome is also an example of dominant negative mutation and haploinsufficiency.
  • Lethal mutations result in the instant death of the developing organism. Lethal mutations can also lead to a substantial loss in the life expectancy of the organism. An example of a disease that is caused by a dominant lethal mutation is Huntington’s disease.
  • Null mutations, also known as Amorphic mutations, are a form of loss-of-function mutations that completely prohibit the gene's function. The mutation leads to a complete loss of operation at the phenotypic level, also causing no gene product to be formed. Atopic eczema and dermatitis syndrome are common diseases caused by a null mutation of the gene that activates filaggrin.
  • Suppressor mutations are a type of mutation that causes the double mutation to appear normally. In suppressor mutations the phenotypic activity of a different mutation is completely suppressed, thus causing the double mutation to look normal. There are two types of suppressor mutations, there are intragenic and extragenic suppressor mutations. Intragenic mutations occur in the gene where the first mutation occurs, while extragenic mutations occur in the gene that interacts with the product of the first mutation[4]. A common disease that results from this type of mutation is Alzheimer's disease.
  • Neomorphic mutations are a part of the gain-of-function mutations and are characterized by the control of new protein product synthesis. The newly synthesized gene normally contains a novel gene expression or molecular function. The result of the neomorphic mutation is the gene where the mutation occurs has a complete change in function.[5]
This figure shows a simplified version of loss-of-function, switch-of-function, gain-of-function, and conservation-of-function mutations.
  1. ^ Reva, Boris; Antipin, Yevgeniy; Sander, Chris (2011-09). "Predicting the functional impact of protein mutations: application to cancer genomics". Nucleic Acids Research. 39 (17): e118–e118. doi:10.1093/nar/gkr407. ISSN 1362-4962. PMC 3177186. PMID 21727090. {{cite journal}}: Check date values in: |date= (help)CS1 maint: PMC format (link)
  2. ^ Housden, Benjamin E.; Muhar, Matthias; Gemberling, Matthew; Gersbach, Charles A.; Stainier, Didier Y. R.; Seydoux, Geraldine; Mohr, Stephanie E.; Zuber, Johannes; Perrimon, Norbert (2017-01). "Loss-of-function genetic tools for animal models: cross-species and cross-platform differences". Nature Reviews Genetics. 18 (1): 24–40. doi:10.1038/nrg.2016.118. ISSN 1471-0056. PMC 5206767. PMID 27795562. {{cite journal}}: Check date values in: |date= (help)CS1 maint: PMC format (link)
  3. ^ Sciences, Board on Life; Studies, Division on Earth and Life; Committee on Science, Technology; Affairs, Policy and Global; Policy, Board on Health Sciences; Council, National Research; Medicine, Institute of (2015-04-13). Gain-of-Function Research: Background and Alternatives. National Academies Press (US). {{cite book}}: |first4= has generic name (help)
  4. ^ Eggertsson, Gudmundur; Adelberg, Edward A (1965-08-01). "MAP POSITIONS AND SPECIFICITIES OF SUPPRESSOR MUTATIONS IN ESCHERICHIA COLI K-12". Genetics. 52 (2): 319–340. doi:10.1093/genetics/52.2.319. ISSN 1943-2631. PMC 1210853. PMID 5324068.{{cite journal}}: CS1 maint: PMC format (link)
  5. ^ Takiar, V.; Ip, C. K. M.; Gao, M.; Mills, G. B.; Cheung, L. W. T. (2017-03). "Neomorphic mutations create therapeutic challenges in cancer". Oncogene. 36 (12): 1607–1618. doi:10.1038/onc.2016.312. ISSN 1476-5594. PMC 6609160. PMID 27841866. {{cite journal}}: Check date values in: |date= (help)CS1 maint: PMC format (link)